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Background and purpose: Deformation and correlated target motion remain challenges for margin recipes
in radiotherapy (RT). This study presents a statistical deformable motion model for multiple targets and
applies it to margin evaluations for locally advanced prostate cancer i.e. RT of the prostate (CTV-p), sem-
inal vesicles (CTV-sv) and pelvic lymph nodes (CTV-ln).
Material and methods: The 19 patients included in this study, all had 7–10 repeat CT-scans available that
were rigidly aligned with the planning CT-scan using intra-prostatic implanted markers, followed by
deformable registrations. The displacement vectors from the deformable registrations were used to cre-
ate patient-speciﬁc statistical motion models. The models were applied in treatment simulations to
determine probabilities for adequate target coverage, e.g. by establishing distributions of the accumu-
lated dose to 99% of the target volumes (D99) for various CTV–PTV expansions in the planning-CTs.
Results: The method allowed for estimation of the expected accumulated dose and its variance of differ-
ent DVH parameters for each patient. Simulations of inter-fractional motion resulted in 7, 10, and 18
patients with an average D99 >95% of the prescribed dose for CTV-p expansions of 3 mm, 4 mm and
5 mm, respectively. For CTV-sv and CTV-ln, expansions of 3 mm, 5 mm and 7 mm resulted in 1, 11 and
15 vs. 8, 18 and 18 patients respectively with an average D99 >95% of the prescription.
Conclusions: Treatment simulations of target motion revealed large individual differences in accumulated
dose mainly for CTV-sv, demanding the largest margins whereas those required for CTV-p and CTV-ln
were comparable.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 344–349For several major tumor sites managed with radiotherapy (RT),
treatment of both primary and elective targets is indicated. These
treatments may be compounded by independent motion and
deformation of the involved targets. Depending on which target
is being used for image-guidance, the uncertainties due to the
residual, uncorrected motion should be accounted for the appro-
priate margin forming the planning target volume (PTV) [1,2]. In
radiotherapy of locally advanced prostate cancer – with the pros-
tate as the primary target (CTV-p), and the elective targets consist-
ing of the seminal vesicles (CTV-sv) and the pelvic lymph nodes
(CTV-ln) – the different motion patterns present a considerable
challenge. The motion of the pelvic lymph nodes is assumed to
be rigid since the lymph nodes are closely related to vascular and
bony anatomy, but therefore move uncorrelated to the prostate[1,8–9]. In contrary, the motion of the seminal vesicles includes
deformations but to what extent the motion is correlated to the
prostate is still unclear [4–7]. Consequently, if assumptions regard-
ing this correlation need to be made beforehand in a motion model,
they can be unreliable.
Although data supporting deformable target motion exist, most
studies addressing the dosimetric effects of residual motion of the
pelvic lymph nodes and/or seminal vesicles have simulated the tar-
get movement as translational shifts of the planned dose distribu-
tion [6,10–13]. Instead, in this paper we propose a statistical
method for treatment simulation involving a deformable motion
model. The method has been introduced to RT by Söhn et al.
[14–15] but so far not been employed for margin evaluations. As
the method requires point correspondence we used a data set con-
sisting of repeat CT scans with target delineations, and where these
delineations were co-registered with a validated algorithm for non-
rigid motion. From the data of voxel displacements, interpolation
and extrapolation of the observed (input) target shapes can bemade
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occurring. No assumptions of which of the motion patterns that
aremost prominent need to bemade beforehand as it was explicitly
handled in the model. The purpose of the study was therefore to
introduce the model of residual target motion still present after im-
age guidance on intra-prostatic markers and apply it for dosimetric
evaluation of margins for the multiple targets in RT of locally ad-
vanced prostate cancer.Materials and methods
Patients
Nineteen patients with locally advanced prostate cancer previ-
ously treated with intensity-modulated RT (IMRT) were included
in the study [16]. Each patient had an image set consisting of a
planning CT as well as 7–10 additional CT scans acquired evenly
distributed throughout their treatment course. All scans were ob-
tained with a slice thickness of 2–3 mm, covering L4 to the anus
and with the patient in supine position using a similar ﬁxation
device as during RT delivery. The patients had three ﬁducial gold
markers implanted in the prostate, which were used for image
guidance. For the planning CT, all but one patient were given
contrast to the bladder for the purpose of better distinguishing
the bladder wall from the prostate gland. During the course of
treatment no bladder or rectum preparation protocol was
followed.
For each CT scan the three clinical target volumes: CTV-p, CTV-
sv and CTV-ln were delineated by an experienced radiation oncol-
ogist [17]; CTV-ln delineations followed the RTOG guidelines [9]
except for the pre-sacral nodes which were omitted. In order to se-
cure consistent delineations, all patients were considered as high
risk patients T3a and all target segmentations for one patient were
performed in a short time interval (usually within one day). Fur-
ther details about these delineations can be found in Thornqvist
et al. [17].Generation of individualized statistical target motion models
The target delineations in the repeat CT scans were used to con-
struct statistical deformable motion models. Our study evaluated
the geometric uncertainties when setup was based on the intra-
prostatic ﬁducial makers. Consequently, all displacements, rigid
as well as non-rigid, were derived relative to the ﬁducial markers.
This choice of setup (e.g. instead of bony anatomy) was motivated
by previous studies [2,18] but a model could also have been estab-
lished from setup based on bony anatomy or soft-tissue
registrations.
For the common reference system of the ﬁducial markers in
each patient, points on all target surfaces in every CT were distrib-
uted with an isotropic resolution of 1 mm. This resulted in target
shape vectors, p consisting of N points, varying between 1500
and 229,700 depending on the size of the target. The residual tar-
get motion after image guidance on ﬁducial markers was obtained
by calculating the point correspondence between the target shape
vectors in the repeat CTs as compared to the planning CT. This was
conducted using an in-house developed framework for non-rigid
registrations [19–20]. In short, the framework used an inverse-con-
sistent version of the symmetric Thin-Plate Spline Robust-Point
Matching (TPS-RPM) algorithm [19–20], where the point corre-
spondence was modeled by soft-assignment, i.e. x points can corre-
spond to y points of the deformed shape. Deterministic annealing
was used to reﬁne the correspondence and transformation itera-
tively, so that each new iteration of the annealing cycle allowed
the transformation to be more ﬂexible and reduced the fuzziness
in the point correspondence [19–20]. The parameters of the TPS-RPM were optimized individually for each of the three targets both
for accuracy, comparing the deviations of the target shape vectors
of the transformed structures to those manually delineated in all
the repeat CTs [19], as well as for inverse consistency. For CTV-p
this resulted in an average ± standard deviation of 0.2 ± 0.2 mm
and 0.1 ± 0.0 mm for the accuracy and inverse consistency, respec-
tively. For CTV-sv the accuracy and inverse consistency were
0.3 ± 0.5 mm and 0.2 ± 0.2 mm and for CTV-ln 0.3 ± 0.5 mm and
0.3 ± 0.2 mm.
Each registration of target surfaces resulted in 3D transforma-
tion vectors for all target points. This residual movement of the tar-
get shape vectors described by the deformation vector ﬁelds from
the TPS-RPM registrations was subsequently analyzed using prin-
cipal component analysis (PCA). The PCA method can be used for
analyzing high dimensional and possibly correlated data [14–15].
The average and the covariance matrix of the target shape vectors
were transformed by the PCA into a set of principal components,
ordered by their ability to capture and account for the variability
of the input data:
psim ¼ pþ
XL
l¼1
clql ð1Þ
where the eigenvectors ql are normalized orthogonal vectors or-
dered by the L largest eigenvalues, kl. These eigenvalues quantiﬁed
the variability described by the components, l = 1...L. From Eq. (1)
new target shapes, psim were generated from a linear combination
of the average target shape vector and the components, by sampling
cl from a normal distribution with a zero mean and a variance
equivalent to kl for each component. In this study all L components
were used and individual PCA motion models were constructed for
each of the three targets (Fig. 1).Treatment simulations for margin evaluations
Treatment simulations were conducted on dose distributions
derived for PTV expansions of the delineated targets in the plan-
ning CT. Uniform CTV-to-PTV expansions ranging from 3 mm to
17 mm were analyzed. In the case of overlapping PTVs a union
was used to create a new PTV. Synthetic dose distributions were
constructed by convolution with a Gaussian kernel of 1.64 multi-
plied by the penumbra width, rp [3], set to 5 mm [7,21]. On the
dose distribution of the planning CT, d(), a new target shape was
generated from the deformable target motion model (Eq. (1)) for
every treatment fraction, k and accumulated into a ﬁnal treatment
dose, Dtreat:
Dtreat ¼
XNfx
k¼1
dðpsimk Þ ð2Þ
where Nfx is the total number of fractions. In addition, treatment
simulations accounting for an imperfect setup were also conducted
by adding a rigid translational shift to the PCA-generated target
shapes. The rigid shifts were sampled from Gaussian distributions
with a mean of zero and with a standard deviation rsetup. For the
prostate, seminal vesicles and pelvic lymph nodes rsetup = 1.0–
1.7 mm was used [22].
For this study the treatment scenario simulated was a dose pre-
scription of 78 Gy to the prostate and 55 Gy to the elective targets
delivered in 37 fractions (Nfx = 37). As Dtreat is accumulated from a
conﬁguration of Nfx different target shapes, other conﬁgurations of
target shapes would possibly lead to a different value of Dtreat.
Therefore, in order to evaluate the distribution of Dtreat in e.g. dose
volume parameters for each patient, each fractionated course of
treatment was run 1000 times using Monte Carlo simulations. Note
that the PCA-based simulations allow for point-correspondance
when assesing the variability of Dtreat. In the following we will
Fig. 1. Schematic presentation of the method of generating new target shapes from variations of the CTVs in the repeat CTs. Here displayed for the seminal vesicles.
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the 1000 simulated treatments and the variability of the dosimet-
ric quantities expressed as 10-/90-percentiles.
Results
For all three targets the distribution of the dose to 99% of the
target volume (D99) of Dtreat for CTV-p, CTV-sv and CTV-ln all
showed smaller variation as the PTV expansions increased (Fig. 2,
Supplementary Fig. S1) expressing increased plan robustness to
geometric uncertainties with larger margin size, as expected. In
the majority of patients the variations of the distribution of D99 ex-
ceeded the variations of the distributions of the target volume
receiving 95% of the prescribed dose (V95%) (Figs. 2 and 3).
The greatest intra-patient variability of D99 was obtained for
CTV-sv (Fig. 2). In addition, large inter-patient variations in margin
expansions were more frequent for this elective target (Figs. 2 and
3). With a 5 mm CTV-to-PTVmargin expansion around CTV-sv nine
of the patients had a D99 >95% of the prescribed dose in 90% of the
simulated treatments with inter-fraction motion (Fig. 2). To further
improve coverage for CTV-sv, a margin expansion of at least 9 mm
was required for all but three patients to have D99 larger than 95%
of the prescribed dose in 90% of the treatments for both simula-
tions with and without setup motion. With an 11 mm margin
expansion the average D99 exceeded 95% of the prescribed dose
for all but two patients and to obtain an average D99 >95% of the
prescription dose in the two remaining patients, a margin expan-
sion of 13 mm was required.Fig. 2. The distributions of D99 from simulations with inter-fraction motion for the pros
lymph node CTV (right) with varying PTV expansions in color. Yellow denotes 3 mm expa
in brown for the seminal vesicles. Average D99 is marked by crosses with 10- and 90-per
the prescription dose. (For interpretation of the reference to colour in this ﬁgure legendAs compared to CTV-sv, CTV-ln displayed a different pattern in
both D99 and V95 of Dtreat as a function of margin size (Figs. 2 and 3).
A 5 mm CTV-to-PTV expansion resulted in all but two of the pa-
tients having a D99 >95% of the prescribed dose in 90% of the sim-
ulated treatments with inter-fraction motion and increasing the
margin to 7 mm resulted in 18 of the patients fulﬁlling this
requirement (Fig. 2). To achieve D99 >95% of the prescribed dose
in 90% of the simulated treatments for all patients, a margin of
15 mm was required.
The impact of setup motion was greatest for the CTV-p resulting
in a reduced average D99 and V95 as well as a wider conﬁdence
interval (Supplementary Figs. S1–S2). This difference was most evi-
dent when using a CTV-to-PTV margin of 4 mm where including
setup motion in the simulations reduced the number of patients
having D99 >95% of the prescribed dose in 90% of the treatment
from 10 to 7 patients (Supplementary Fig. S1). In addition, for sim-
ulations including setup motion of CTV-p a large incremental
improvement in both D99 and V95% was found when expanding
margins from 4 mm to 5 mm; a 4 mm margin in 17 of 19 patients
having an average D99 larger than 95% of the prescription dose
whereas with a 4 mm margin, this criterion was satisﬁed for only
seven patients. Expanding CTV-p by 6 mm resulted in 18 of 19 pa-
tients with a D99 exceeding 95% of the prescribed dose in 90% of all
simulated treatments (Supplementary Fig. S1), irrespective if setup
motion was included in the simulations.
Finally, if similar criteria to that used in margin recipes were ap-
plied to the result from our treatment simulations e.g. D99 >95% of
the prescribed dose as well as coverage of the 95% isodose for thetate CTV (left) and for the seminal vesicle CTV (middle) as well as D99 for the pelvic
nsion, orange 5 mm, red 7 mm (6 mm in case of prostate) and an additional 11 mm
centiles in bars. Dashed lines denote the prescribed dose and dashed-dotted 95% of
, the reader is referred to the web version of this article.)
Fig. 3. The distribution of the volume receiving 95% of the prescribed dose (V95%) for simulations with inter-fraction, for prostate CTV (left), seminal vesicles CTV (middle row)
and the pelvic lymph node CTV (right) for varying PTV expansions in color. Yellow denotes 3 mm expansion, orange 5 mm, red 7 mm (6 mm in case of prostate) and an
additional 11 mm in brown for the seminal vesicles. Average V95% is marked by crosses with the 10- and 90-percentiles in bars. (For interpretation of the reference to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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expansions of 5–6 mm for the prostate, 11 mm for the seminal ves-
icles and 5 mm for the pelvic lymph nodes were needed.
Discussion
In this study we have used a statistical motion model to evalu-
ate margin requirements for the two elective targets, the seminal
vesicles and the pelvic lymph nodes and the primary target of
the prostate, when IGRT is based on the prostate. Apart from allow-
ing deformations the PCA modeling has other beneﬁts in treatment
simulations for margin evaluations.
One beneﬁt was that no prior information about the relative
importance of the target motion patterns were needed as this
was explicitly part of the PCA. To the best of our knowledge, this
study is the ﬁrst to give CTV-to-PTV margin recommendations
from treatment simulations accounting for residual target motion
including deformations in male whole pelvic RT. For this treat-
ment, assumptions regarding target motion patterns for individual
patients could be error prone as previous studies have revealed
large individual differences in motion patterns. Large inter-patient
differences were also evident in our dosimetric evalution, espe-
cially for CTV-sv (Figs. 2 and 3). Therefore, to account for these
variations for the majority of the patients demanded larger mar-
gins as compared to both CTV-ln and CTV-p. Acknowledging the
deformations of the seminal vesicles and the inadequacy of the
conventional margin recipe to account for such motion [3], earlier
studies have also applied the deformation vector ﬁelds for evalua-
tion of margins [7,23]. Although not including the entire seminal
vesicles, Meijer et al. suggested similar margin expansions: 3–
6 mm for the prostate and 8 mm for the seminal vesicles [23]. In
comparison, our data show that when the entire seminal vesicles
were included a 9 mm margin expansion would be adequate, de-
duced from the distributions of D99 as well as V95, for all but three
of the patients (Figs. 2 and 3). Investigating margins for the entire
seminal vesicles with synthetic dose distributions, as in our ap-
proach, Mutanga et al. found 8 mm seminal vesicle margin expan-
sions to be insufﬁcient [7].
Another beneﬁt of the statistical motion model was that in
addition to the average accumulated dose to the target we could
quantify the variability of this distribution (expressed as 10–90
percentiles) around the average. If the number of inputs available
for the patient < the number of fractions, these inputs can be re-
garded as a sample of each patient’s underlying distribution of pos-
sible geometries. Consequently, the accumulated target dose
(Dtreat) is also a variable with its own distribution. Our results show
that these intra-patient variations were greatest for CTV-sv. As
compared to the increase in average D99 and V95 with increasingmargin expansion, the variability had only a slow reduction with
larger margin size for the majority of the patients (Figs. 2 and 3).
Another study employing treatment simulations of margins for
the prostate and the seminal vesicles revealed much larger intra-
patient variations in comparison to our results [7]. These discrep-
ancies with the study of Mutanga et al. could also be explained
by their low number of samples (i.e. CT scans) which can exagger-
ate the variance. Especially since this sample was applied to esti-
mate both random and systematic displacements, used
independently in their simulations.
In our study we assumed that a sample of 19 patients with their
repeat imaging was representative for this group of patients trea-
ted with locally advanced prostate cancer. One distinct outlier of
the sample (patient 9) was identiﬁed, most noticeable for CTV-ln,
where even a margin expansion of 9 mm would result in an aver-
age D99 of 40 Gy, besides leading to the 95% isodose line only cov-
ering 91% of the CTV-ln when simulating inter-fraction motion. To
increase the coverage of the CTV-ln to 99% would require a margin
expansion of 15 mm. This patient also required the largest margins,
13 mm, for full dose coverage of the CTV-sv. The need for these
large expansions was explained by a shift of 8 mm in the caudal
and posterior directions in combination with a rectal gas volume
introducing a systematic shift for both the target shapes of the
seminal vesicles and the caudal part of the pelvic lymph nodes in
the repeat CTs as compared to the planning CT. For such systematic
change in anatomy, re-planning instead of applying large margin
expansions would probably be more beneﬁcial for the patient.
For the prostate, although positioning was based on intra-prostatic
ﬁducial markers, one patient required CTV-to-PTV expansions of
6 mm to achieve an average accumulated dose >95% of the pre-
scribed dose. This patient (patient 19) displayed a consistently lar-
ger prostate volume delineated for the repeat CT in comparison to
the CTV in the planning CT. Most of the differences were in the cra-
nial part of the prostate which could be caused by differences in
location of the CT slices in relation to the anatomy when acquiring
the images as well as delineation uncertainties arising from the dif-
ﬁculty in differentiating between bladder wall and prostate base
with (planning CT) and without contrast (repeat CTs) injected to
the bladder. Indeed, uncertainties in contouring are inevitably
introduced when performing manual segmentation of CTVs in a re-
peat CT-set [24,25]. Motion uncertainties may therefore partly be
confounded by uncertainties in delineation in this study, although
we did our best to secure consistent target delineations. A PTV
should per deﬁnition incorporate all uncertainties that can degen-
erate the intended prescription dose to the targets. However, as
our focus was evaluation of margins to compensate residual target
motion we opted for reducing the effect of delineation uncertain-
ties by letting the same oncologist delineate the targets for one
348 Statistical deformable motion model for margin evaluations when irradiating multiple targetspatient cohesively in time. It should therefore be noted that as the
delineations of the targets all were made by the same radiation
oncologist, the modeled margin expansions do not take delineation
uncertainties between different radiation oncologists into account.
In addition, our margin expansion results for CTV-ln might not be
applicable if other delineation guidelines [25] are used. These
guidelines were developed to increase consensus following a study
revealing large variations in CTV-ln delineations, especially for the
pre-sacral nodes (omitted in our study) [26]. For the prostate,
reproducibility of delineation has also been studied and shown to
be comparable to the smallest direction (left–right) of prostate mo-
tion when compared to bony anatomy [27–29]. For the seminal
vesicles the motion/deformations have shown to be at least twice
as large as the magnitude of the intra-observer delineation varia-
tions [5].
The ability of the deformable registration algorithm to accu-
rately calculate the residual motion was another component that
inﬂuenced the modeling and results. The symmetric TPS-RPM algo-
rithm has previously been validated for pelvic as well as head and
neck cancers [19–20]. The evaluation included accuracy (devia-
tions between the transformed and the manually delineated struc-
ture), inverse consistency as well as comparison of anatomical
landmarks for organs presenting small and large volume changes
[19–20]. These studies revealed that even for a highly deformable
organ e.g. the bladder and cervix, the majority of the evaluations
gave errors less than 5 mm [19–20]. For more rigidly moving organ
these numbers were further improved.
The number of repetitions used in the Monte Carlo simulations
inﬂuences the dosimetric accuracy of our results. Ideally the num-
ber of simulations should be as large as feasible in order to mini-
mize the statistical uncertainties. However, our choice reﬂected a
trade-off between minimizing the statistical uncertainties and
manageable calculation times; for selected patients we veriﬁed
that the introduced errors were indeed minimal (data not shown).
Another potential weakness of our study is the modeling of set-
up motion. Intra-fraction motion has been thoroughly studied for
the prostate [22,29–34] but for the two elective targets the data
are very limited. We simpliﬁed the simulation of setup motion to
be a shift, equally probable in all directions and additive to the
PCA motion model. This might not be true even for the prostate,
where rectum ﬁlling has been shown to inﬂuence prostate motion
[33–34], i.e. not all generated prostate shapes have the same distri-
bution and magnitude of shifts. The strongest impact of the setup
motion was observed for the prostate. This was due to the shorter
length of the deformation vectors, which on average for the pros-
tate was 2.8 mm as compared to 4.7 mm for the seminal vesicles
and 4.4 mm for the pelvic lymph nodes.Conclusion
In this study we have introduced a statistical deformable mo-
tion model to evaluate patient-speciﬁc target motion and deforma-
tions. Applied on an image material from a series of locally-
advanced prostate cancer patients, we found the inter-patient vari-
ations to be most pronounced for the CTV-sv. Fulﬁlling the criteria
of D99 >95% of the prescribed dose as well as coverage of the 95%
isodose for the average treatment in the majority (>89%) of pa-
tients, CTV-to-PTV expansions of 5–6 mm for the prostate,
11 mm for the seminal vesicles and 5 mm for the pelvic lymph
nodes were found to be required.Conﬂict of interest
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